#Ireland #Dublin #share repurchase #Jazz Pharmaceuticals #Exchangeable Notes

Jazz Pharmaceuticals Announces Upsized Private Offering

Jazz Pharmaceuticals plc, a prominent global biopharmaceutical company, recently revealed the pricing details for a substantial private offering of exchangeable senior notes. This offering, amounting to an impressive $1.1 billion, marks an upsizing from the previously noted $1.0 billion. The exchangeable senior notes carry an interest rate of 1.875% and are set to mature in 2032.

The issuance will be carried out by Jazz Investments I Limited, a wholly-owned subsidiary of Jazz Pharmaceuticals and is aimed exclusively at qualified institutional buyers. The listed notes will gain interest, distributed semiannually on March 15 and September 15, starting in 2027. An exciting feature of this offering is the opportunity for initial purchasers to buy additional notes, totaling $150 million, within a two-week period from the initial issue date.

Jazz Pharmaceuticals intends to utilize the net proceeds from this offering for general corporate purposes. They anticipate a net gain of approximately $1.079 billion, dependent on the market conditions and potential additional purchases by the initial buyers, which could inflate the total to around $1.226 billion.

In a strategic maneuver to optimize their financial portfolio, Jazz Pharmaceuticals has disclosed plans for concurrent ordinary share repurchases amounting to $225 million. These repurchases will occur alongside the pricing of the notes and will involve transactions with participants of the note offerings. The repurchase price is set at $249.29 per ordinary share, reflecting the last recorded sale price prior to the announcement.

This dual strategy not only strengthens Jazz Pharmaceuticals’ balance sheet but also ensures that the company remains solidly positioned in the competitive biopharmaceutical landscape. Jazz’s ordinary shares are subject to fluctuations, influenced by the timing of the share repurchase strategies. Although there is no certainty about the overall impact on share prices, these moves are expected to align with Jazz Pharmaceuticals' broader commitment to innovation and patient care.

Key Features of the Offering

• - The notes will accrue interest at 1.875%, payable biannually.
• - Maturity is set for September 15, 2032, with specific terms for early exchange, redemption, or repurchase.
• - The initial exchange rate stands at 2.8150 ordinary shares per $1,000 principal amount of notes.
• - The offering is fully guaranteed, ensuring security and priority rights in payment over lower-ranking debts.

Company Overview

Founded on the principle of pioneering medical breakthroughs, Jazz Pharmaceuticals focuses on developing innovative therapies, especially for conditions that are rare or lack adequate treatment options. Their portfolio includes essential medicines driving advancements in specialties like oncology, epilepsy, and sleep disorders. Headquartered in Dublin, Ireland, Jazz remains committed to improving the quality of life for patients across the globe through its dedicated research and extensive pipeline.

Forward-Looking Statements & Risks

While Jazz Pharmaceuticals is optimistic about the prospects stemming from this offering, they caution stakeholders about typical risks associated with forward-looking statements, underscoring that actual outcomes may diverge significantly due to various market or operational uncertainties. Such proactive communications keep investors informed about strategic decisions in light of market dynamics.

Conclusion

Jazz Pharmaceuticals’ recent financial maneuvers signal a robust strategy aimed at enhancing corporate structure and driving growth, maintaining their trajectory as a leading innovator in the biopharmaceutical sector. Stakeholders will be keenly monitoring the implications of these actions on the company’s market posture and overall valuation in the coming years.